Market
Which company will announce a capsid inhibitor similar to lenacapavir by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Public announcements and press releases from pharmaceutical companies
Story
Lenacapavir Named Science's Breakthrough of 2024 for HIV Prevention
Dec 15, 2024, 03:44 PM
The injectable HIV drug lenacapavir has been recognized by the journal 'Science' as the Breakthrough of the Year for 2024. Developed by Gilead Sciences, lenacapavir targets the HIV capsid, a protein shell that protects the virus's genetic material, preventing the virus from replicating within human cells. This drug, administered as a subcutaneous injection every six months, has shown remarkable efficacy in preventing HIV infection, with trials reporting a 100% success rate in African adolescent girls and young women, and a 99.9% effectiveness in gender-diverse individuals. Lenacapavir's unique mechanism of action, as a capsid inhibitor, sets it apart from traditional antiretroviral drugs, offering hope for significantly reducing global HIV infection rates when used as pre-exposure prophylaxis (PrEP).
View original story
Similar markets
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Approved in USA only • 25%
Not approved in USA or EU • 25%
Approved in both USA and EU • 25%
Approved in EU only • 25%
North America • 25%
Asia • 25%
Africa • 25%
Europe • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
European Union • 25%
United States • 25%
South Africa • 25%
Other • 25%
South Africa • 25%
United States • 25%
Other • 25%
India • 25%
UNAIDS • 25%
PEPFAR • 25%
Global Fund • 25%
WHO • 25%
Other • 25%
USA • 25%
UK • 25%
South Africa • 25%
Clinics • 25%
Community health programs • 25%
Pharmacies • 25%
Hospitals • 25%
PEPFAR • 25%
Global Fund • 25%
Other • 25%
Gilead Sciences • 25%